U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07776457) titled 'Substance Use in Pregnancy - Optimizing Retention in Treatment by Maximizing Opportunities for Management' on Aug. 11.
Brief Summary: Overdose is a national top-three leading cause of pregnancy-associated death, and maternal substance use disorder (SUD) accounts for an estimated $1.5 billion in healthcare spending each year. Treatment with medication and behavioral therapy lowers morbidity and overdose risk. However, studies have shown 55% to 80% of patients stop treatment within one year postpartum. Additionally, as a result of systemic inequities, historically marginalized patients are at greatest risk of overdose or death. We are...